MAGEA1 and ovarian carcinoma: MAGE-A1, MAGE-A3, MAGE-A6, and MAGE-A9 are expressed in a variety of different tumor types, including in melanomas (MAGE-A1: 16%–20% in primary tumors and 48%–51% in metastases, MAGE-A3: 60%–75%), non-small cell lung carcinomas (MAGE-A1: 27%–46%, MAGE-A3: 38%–55%, MAGE-A6: 26%), breast carcinomas (MAGE-A9: 45%, MAGE-A3/A6: 10%–15%, MAGE-A1: 6%), ovarian carcinomas (MAGE-A1: 15%–53%, MAGE-A3: 36%–37%, MAGE-A9: 52%), colon carcinomas (MAGE-A1: 12%–30%, MAGE-A3: 20%–27%), and MM (MAGE-A1: <10%–26%, MAGE-A3/A6: 37%–41% in primary tumor and 77% in metastases).18